Dataset Information


Treatment of intrabony periodontal defects using rhFGF-2 in combination with deproteinized bovine bone mineral or rhFGF-2 alone: A 6-month randomized controlled trial.

ABSTRACT: AIM:To evaluate the use of recombinant human fibroblast growth factor (rhFGF)-2 in combination with deproteinized bovine bone mineral (DBBM) compared with rhFGF-2 alone, in the treatment of intrabony periodontal defects. MATERIALS AND METHODS:Patients with periodontitis who had received initial periodontal therapy and had intrabony defects of ? 3 mm in depth were enrolled. Sites were randomly assigned to receive a commercial formulation of 0.3% rhFGF-2 + DBBM (test) or rhFGF-2 alone (control). Clinical parameters and a patient-reported outcome measure (PROM) were evaluated at baseline and at 3 and 6 months postoperatively. RESULTS:Twenty-two sites in each group were evaluated. A significant improvement in clinical attachment level (CAL) from baseline was observed in both groups at 6 months postoperatively. CAL gain was 3.16 ± 1.45 mm in the test group and 2.77 ± 1.15 mm in the control group, showing no significant difference between groups. Radiographic bone fill was significantly greater in the test group (47.2%) than in the control group (29.3%). No significant difference in PROM between groups was observed. CONCLUSIONS:At 6 months, no significant difference in CAL gain or PROM between the two treatments was observed, although combination therapy yielded an enhanced radiographic outcome.


PROVIDER: S-EPMC6899590 | BioStudies | 2019-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6519096 | BioStudies
2020-01-01 | S-EPMC7014298 | BioStudies
2018-01-01 | S-EPMC6220803 | BioStudies
2017-01-01 | S-EPMC5501118 | BioStudies
2019-01-01 | S-EPMC6660941 | BioStudies
2017-01-01 | S-EPMC5324386 | BioStudies
2017-01-01 | S-EPMC5551323 | BioStudies
2020-01-01 | S-EPMC7109495 | BioStudies
2013-01-01 | S-EPMC5715458 | BioStudies
2019-01-01 | S-EPMC6920033 | BioStudies